Trial Profile
Is Sorafenib beneficial in patients with post-transplant hepatocellular carcinoma recurrence.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 30 Nov 2018 New trial record
- 05 Nov 2018 Primary endpoint (efficacy of sorafenib in patients with no otherwise treatable Hepatocellular carcinoma recurrence after Liver transplant compared to best supportive care, according to survival time) has been met as per results published in the Journal of Korean Medical Science
- 05 Nov 2018 Results published in the Journal of Korean Medical Science